TEVA($42.9B) has a higher market cap than BIOA($389M). TEVA has higher P/E ratio than BIOA: TEVA (61.82) vs BIOA (1.37). TEVA YTD gains are higher at: 18.840 vs. BIOA (-35.828). TEVA has higher annual earnings (EBITDA): 2.59B vs. BIOA (-93.93M). TEVA has more cash in the bank: 3.66B vs. BIOA (319M). BIOA has less debt than TEVA: BIOA (2.84M) vs TEVA (16.9B). TEVA has higher revenues than BIOA: TEVA (17.3B) vs BIOA (10.4M).

	BIOA	TEVA	BIOA / TEVA
Capitalization	389M	42.9B	1%
EBITDA	-93.93M	2.59B	-4%
Gain YTD	-35.828	18.840	-190%
P/E Ratio	1.37	61.82	2%
Revenue	10.4M	17.3B	0%
Total Cash	319M	3.66B	9%
Total Debt	2.84M	16.9B	0%

FUNDAMENTALS RATINGS

BIOA vs TEVA: Fundamental Ratings

	BIOA	TEVA
OUTLOOK RATING 1..100	57	77
VALUATION overvalued / fair valued / undervalued 1..100	41 Fair valued	70 Overvalued
PROFIT vs RISK RATING 1..100	86	12
SMR RATING 1..100	96	72
PRICE GROWTH RATING 1..100	65	40
P/E GROWTH RATING 1..100	6	12
SEASONALITY SCORE 1..100	70	n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOA's Valuation (41) in the Chemicals Specialty industry is in the same range as TEVA (70) in the Pharmaceuticals Generic industry. This means that BIOA’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (12) in the Pharmaceuticals Generic industry is significantly better than the same rating for BIOA (86) in the Chemicals Specialty industry. This means that TEVA’s stock grew significantly faster than BIOA’s over the last 12 months.

TEVA's SMR Rating (72) in the Pharmaceuticals Generic industry is in the same range as BIOA (96) in the Chemicals Specialty industry. This means that TEVA’s stock grew similarly to BIOA’s over the last 12 months.

TEVA's Price Growth Rating (40) in the Pharmaceuticals Generic industry is in the same range as BIOA (65) in the Chemicals Specialty industry. This means that TEVA’s stock grew similarly to BIOA’s over the last 12 months.

BIOA's P/E Growth Rating (6) in the Chemicals Specialty industry is in the same range as TEVA (12) in the Pharmaceuticals Generic industry. This means that BIOA’s stock grew similarly to TEVA’s over the last 12 months.

TECHNICAL ANALYSIS

Technical Analysis

	BIOA	TEVA
RSI ODDS (%)	2 days ago 90%	2 days ago 59%
Stochastic ODDS (%)	2 days ago 90%	2 days ago 74%
Momentum ODDS (%)	2 days ago 69%	2 days ago 78%
MACD ODDS (%)	2 days ago 82%	2 days ago 54%
TrendWeek ODDS (%)	2 days ago 77%	2 days ago 73%
TrendMonth ODDS (%)	2 days ago 78%	2 days ago 71%
Advances ODDS (%)	11 days ago 84%	4 days ago 74%
Declines ODDS (%)	2 days ago 79%	9 days ago 68%
BollingerBands ODDS (%)	2 days ago 88%	N/A
Aroon ODDS (%)	2 days ago 88%	2 days ago 75%

COMPARISON

Comparison

Sep 12, 2026

Stock price -- (BIOA: $8.49 vs. TEVA: $37.09)

Brand notoriety: BIOA: Not notable vs. TEVA: Notable

Both companies represent the Pharmaceuticals: Generic industry

Current volume relative to the 65-day Moving Average: BIOA: 70% vs. TEVA: 54%

Market capitalization -- BIOA: $388.75M vs. TEVA: $42.89B

BIOA [@Pharmaceuticals: Generic] is valued at $388.75M. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $42.89B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $63.66B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOA’s FA Score shows that 1 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).

BIOA’s FA Score: 1 green, 4 red.
TEVA’s FA Score: 2 green, 3 red.

According to our system of comparison, TEVA is a better buy in the long-term than BIOA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOA’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 3 bullish TA indicator(s).

BIOA’s TA Score: 5 bullish, 3 bearish.
TEVA’s TA Score: 3 bullish, 4 bearish.

According to our system of comparison, BIOA is a better buy in the short-term than TEVA.

Price Growth

BIOA (@Pharmaceuticals: Generic) experienced а -11.47% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +2.01% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -5.31%. For the same industry, the average monthly price growth was -4.84%, and the average quarterly price growth was +30.17%.

Reported Earning Dates

BIOA is expected to report earnings on Nov 05, 2026.

TEVA is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-5.31% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three

BIOA

Daily Signal:

Gain/Loss:

TEVA

Setup

Daily Signal:

Description

Gain/Loss:

Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)

VIEW DETAILS VIEW DETAILS

VIEW FOR FREE VIEW FOR FREE

Interact to see
Advertisement

Interesting Tickers

MFs / NAME	Price $	Chg $	Chg %
		1 Day
AFEGX	52.66	0.46	+0.88%
American Century Large Cap Equity G
IYSIX	25.50	0.21	+0.83%
Nomura Small Cap Growth Institutional
CMNIX	16.31	0.02	+0.12%
Calamos Market Neutral Income I
RSSYX	28.10	N/A	N/A
Victory RS Select Growth Y
GSCOX	34.61	N/A	N/A
Goldman Sachs Small Cap Gr Insghts C

BIOA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.

Ticker / NAME	Correlation To BIOA	1D Price Change %
BIOA	100%	-1.85%
UPC - BIOA	43% Loosely correlated	+12.37%
NBIX - BIOA	38% Loosely correlated	-0.22%
TKNO - BIOA	26% Poorly correlated	-2.89%
HROW - BIOA	23% Poorly correlated	-5.74%
TEVA - BIOA	23% Poorly correlated	+2.04%
More